mitotane has been researched along with carboplatin in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Baudin, E; Berdelou, A; Caramella, C; Hescot, S; Leboulleux, S; Lombes, M; Paci, A | 1 |
Albany, C; Chovanec, M; Hahn, N; Taza, F | 1 |
Fan, XX; Li, ZH; Wang, L; Wang, XY; Weng, Y; Yan, L; Zhang, SL | 1 |
3 other study(ies) available for mitotane and carboplatin
Article | Year |
---|---|
Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient.
Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Humans; Middle Aged; Mitotane; Survival Rate; Treatment Outcome | 2017 |
Long-Term Survival in a Patient With Metastatic DDR2-Positive Adrenal Cortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Carboplatin; Combined Modality Therapy; Discoidin Domain Receptor 2; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Male; Middle Aged; Mitotane; Mutation; Neoplasm Metastasis; Nephrectomy; Tomography Scanners, X-Ray Computed | 2017 |
Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Carboplatin; Etoposide; Humans; Male; Mitotane | 2023 |